Astrazeneca Uk Limited

Reporting payments is a legal requirement; large totals often reflect large product portfolios.

$19Mgeneral payments (2019-2025)

$192Kresearch payments (2019-2025)

4,475clinicians paid

General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.

General payments by year

2019 $2.4M

2020 $1.5M

2021 $1.4M

2022 $2.3M

2023 $2.9M

2024 $3.7M

2025 $4.3M

General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.

Products most associated with its payments

Specialties it works with most

Medical Oncology $2.6M

Hematology & Oncology $2.2M

Pulmonary Disease $1.5M

Cardiovascular Disease $1.2M

Internal Medicine $1.2M

Rheumatology $1.1M

Clinicians with the largest reported totals

Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.

Clinician	Location	Specialty	General payments (2019-2025)
David Horn	Philadelphia, PA	Infectious Disease	$931,157.50
Ira Smalberg	Santa Monica, CA	Diagnostic Radiology	$193,125.00
Marilyn Pike	Boston, MA	Rheumatology	$171,171.33
Peter Weller	Boston, MA	Internal Medicine	$152,850.00
Dinesh Khanna	Ann Arbor, MI	Rheumatology	$145,711.72
Neal Shore	Myrtle Beach, SC	Urology	$142,115.66
John Oppenheimer	Cedar Knolls, NJ	Allergy	$141,054.00
Christopher Cooper	Los Angeles, CA	Pulmonary Disease	$138,708.71
Charu Aggarwal	Philadelphia, PA	Hematology & Oncology	$134,253.45
Jeffrey Kanne	Madison, WI	Diagnostic Radiology	$133,150.00

What this means, and what it doesn't

These payments are legal and common. Drug and device makers routinely pay for meals at educational events, consulting, speaking, travel, and research. Companies are required by federal law to report them; that's why this data exists.
A payment is not evidence of wrongdoing. Most clinicians who accept industry payments provide excellent care. Research payments in particular often reflect participation in clinical trials.
Context beats raw numbers. A few hundred dollars in sandwiches over several years is typical. What's worth understanding is scale, source, and purpose, which is what this page shows.
The data comes from companies, not doctors. Figures are "as reported to CMS" by the paying companies. Clinicians can dispute records through CMS's official process.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.